17th February 2022
February is Oesophageal Cancer Awareness Month. At Barts Cancer Institute, Queen Mary University of London, a key area of research focus is on a condition that can precede oesophageal cancer called Barrett’s oesophagus.
Read more10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more25th January 2022
Researchers from Barts Cancer Institute at Queen Mary University of London, led by Dr Angus Cameron, have found a way to modulate the invasive behaviour of pancreatic cancer by targeting a non-cancerous cell type found within pancreatic tumours. The findings, published in Cell Reports, provide valuable insights into the biology of pancreatic cancer progression, and could help to drive improvements in cancer treatment.
Read more6th January 2022
Researchers from Barts Cancer Institute at Queen Mary University of London, the Moffitt Cancer Center and the University of Southern California, have developed a new method that measures subtle changes to the genetic code of cells (called DNA methylation) to study the dynamics of what happens to cells within our bodies over time. The new method, published in Nature Biotechnology, provides a way to measure the birth and death of human cells, making it possible to trace cell lineage and evolution.
Read more6th December 2021
Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.
Read more1st November 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and King’s College Hospital have shown that a new computer-based algorithm can rank drugs used to treat primary liver cancer, based on their efficacy in reducing cancer cell growth.
Read more